JP2024531387A5 - - Google Patents
Info
- Publication number
- JP2024531387A5 JP2024531387A5 JP2024510331A JP2024510331A JP2024531387A5 JP 2024531387 A5 JP2024531387 A5 JP 2024531387A5 JP 2024510331 A JP2024510331 A JP 2024510331A JP 2024510331 A JP2024510331 A JP 2024510331A JP 2024531387 A5 JP2024531387 A5 JP 2024531387A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- cancer
- days
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021902557A AU2021902557A0 (en) | 2021-08-17 | Combination radiotherapy | |
| AU2021902557 | 2021-08-17 | ||
| AU2021902582 | 2021-08-18 | ||
| AU2021902582A AU2021902582A0 (en) | 2021-08-18 | Combination radiotherapy (2) | |
| PCT/AU2022/050911 WO2023019308A1 (en) | 2021-08-17 | 2022-08-17 | Combination radiotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531387A JP2024531387A (ja) | 2024-08-29 |
| JP2024531387A5 true JP2024531387A5 (https=) | 2025-08-20 |
Family
ID=85239299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024510331A Pending JP2024531387A (ja) | 2021-08-17 | 2022-08-17 | 併用放射線療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240374764A1 (https=) |
| EP (1) | EP4387667A1 (https=) |
| JP (1) | JP2024531387A (https=) |
| KR (1) | KR20240049818A (https=) |
| AU (1) | AU2022328456A1 (https=) |
| CA (1) | CA3227836A1 (https=) |
| IL (1) | IL310848A (https=) |
| MX (1) | MX2024002093A (https=) |
| WO (1) | WO2023019308A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025111661A1 (en) * | 2023-12-01 | 2025-06-05 | Telix Pharmaceuticals (Innovations) Pty Ltd | Novel radiolabelled antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018153975A1 (en) * | 2017-02-24 | 2018-08-30 | Bayer As | Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor |
| RU2765997C2 (ru) * | 2017-03-30 | 2022-02-07 | Мерк Патент Гмбх | Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования |
| MX2020011684A (es) * | 2018-05-04 | 2020-12-10 | Merck Patent Gmbh | Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer. |
| ES3008232T3 (en) * | 2019-07-30 | 2025-03-21 | Xrad Therapeutics Inc | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
-
2022
- 2022-08-17 IL IL310848A patent/IL310848A/en unknown
- 2022-08-17 JP JP2024510331A patent/JP2024531387A/ja active Pending
- 2022-08-17 KR KR1020247008814A patent/KR20240049818A/ko active Pending
- 2022-08-17 EP EP22857141.0A patent/EP4387667A1/en active Pending
- 2022-08-17 CA CA3227836A patent/CA3227836A1/en active Pending
- 2022-08-17 MX MX2024002093A patent/MX2024002093A/es unknown
- 2022-08-17 AU AU2022328456A patent/AU2022328456A1/en active Pending
- 2022-08-17 US US18/684,604 patent/US20240374764A1/en active Pending
- 2022-08-17 WO PCT/AU2022/050911 patent/WO2023019308A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100389825C (zh) | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 | |
| Navarro-Teulon et al. | General overview of radioimmunotherapy of solid tumors | |
| US11970542B2 (en) | Bispecific antibodies specific for treating hematological malignancies | |
| US12133849B2 (en) | Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha- emitting radioimmunotherapeutic | |
| Pandit-Taskar | Targeted radioimmunotherapy and theranostics with alpha emitters | |
| JP2022090047A (ja) | 血液悪性疾患を処置するための低用量抗体に基づく方法 | |
| O'Donnell et al. | Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6 | |
| Staudacher et al. | Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates | |
| Geller et al. | Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R) | |
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| Karimian et al. | Mathematical modeling of preclinical alpha-emitter radiopharmaceutical therapy | |
| Sharkey et al. | Biological considerations for radioimmunotherapy | |
| JP2024531387A5 (https=) | ||
| Li et al. | The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin | |
| JP2025143266A (ja) | 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法 | |
| AU2006242245B2 (en) | Combination therapy in the treatment of cancer | |
| EP1091757B1 (en) | Alpha emitting constructs and uses thereof | |
| Parihar et al. | Radionuclide therapy of lymphomas | |
| ZA200704642B (en) | Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer | |
| DeNardo | Radioimmunotherapy in the Treatment of Metastatic Breast | |
| Abbas | Comparison of High-and Low-LET Radioimmunotherapy in HER-2 positive Carcinomas | |
| HK40018488A (en) | Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic | |
| Dearling et al. | Antinbody directed radioisotope therapy | |
| Chatterjee et al. | Immunotherapeutic Strategies, Radiotherapy, and Targeted Radionuclide Therapy Approaches for the Treatment of Multiple Myeloma | |
| Mihailović et al. | Current concepts of radioimmonotherapy for lymphoma |